Risk Factors for Developing Langerhans Cell Histiocytosis in Adults
The primary established risk factor for developing pulmonary Langerhans cell histiocytosis (PLCH) in adults is cigarette smoking, which is present in the vast majority of single-system pulmonary cases. 1
Smoking as the Dominant Risk Factor
Smoking is the most clearly defined environmental risk factor for adult LCH, specifically for pulmonary disease. The 2022 international expert consensus guidelines explicitly classify single-system pulmonary LCH as "predominantly smoking related" 1. This association is so strong that:
- A presumptive diagnosis of PLCH can be made based on typical radiologic findings on high-resolution CT in a smoker, even without biopsy in certain circumstances 1
- PLCH patients have a high incidence of concomitant lung carcinomas, likely attributable to their smoking history 1
- Some cases show remission upon smoking cessation 1
Important caveat: While smoking is clearly linked to pulmonary LCH, recent molecular studies have identified MAPK pathway alterations in 85% of PLCH lesions (including BRAF-V600E in 36-50%), confirming that even smoking-associated PLCH is fundamentally a clonal neoplastic process 1. This suggests smoking may modulate disease expression rather than being the sole causative factor.
Association with Other Malignancies
Adults with LCH have a significantly elevated risk of concomitant hematologic and solid organ malignancies, which may represent a shared pathogenic mechanism rather than traditional "risk factors" 1:
Hematologic Malignancies
- Myeloid neoplasms (acute myeloid leukemia, myeloproliferative neoplasms, chronic myelomonocytic leukemia)
- Myelodysplastic syndrome 2, 3
- Lymphomas 1, 2
Solid Organ Malignancies
- Lung cancer (particularly in PLCH patients with smoking history) 1
- Thyroid cancer (especially papillary thyroid cancer with BRAF-V600E mutations) 1
- Renal cell carcinoma 1
Clinical implication: The association between LCH and hematologic disorders may reflect a common bone marrow precursor differentiating along different cell lines 2, 3. A Canadian cohort reported concomitant hematological malignancies in 3/11 ECD patients and 3/60 LCH patients 4.
Age-Related Considerations
Younger age at diagnosis (< 30 years) is associated with increased relapse risk in unifocal LCH, with 3-year progression-free survival of 52.2% versus 97.0% in older patients (p = 0.005) 5. However, this represents a prognostic factor rather than a risk factor for developing the disease.
Limited Evidence for Other Risk Factors
The evidence for other risk factors in adults is extremely limited. One exploratory pediatric study (not directly applicable to adults) suggested associations with:
- Maternal urinary tract infection during pregnancy
- Feeding problems during infancy
- Blood transfusions during infancy
- Protective effect of supplemental vitamins 6
These pediatric findings should not be extrapolated to adult-onset LCH, as the disease biology and presentation differ substantially between age groups.
Molecular Drivers vs. Environmental Risk Factors
It is critical to distinguish between molecular drivers and environmental risk factors. LCH is fundamentally a clonal myeloid neoplasm driven by MAPK pathway mutations (BRAF-V600E in ~50%, with MAP2K1, ARAF, NRAS, KRAS, and kinase fusions in others) 1, 7, 5. These are acquired somatic mutations rather than inherited risk factors.
Clinical Surveillance Recommendations
Given the association with second malignancies, clinicians should maintain heightened surveillance for hematologic and solid organ malignancies at any time point (before, during, or after) LCH diagnosis 1. This is particularly important for: